# Rotaxanes comprising cyclic phenylenedioxydiacetamides and secondary mono- and bis-dialkylammonium ions: Effect of macrocyclic ring size on pseudorotaxane formation

Takanori Nakamura,<sup>a</sup> Yuka Mori,<sup>a</sup> Masaya Naito,<sup>a</sup> Yukari Okuma,<sup>a</sup> Shinobu Miyagawa,<sup>a</sup> Hikaru Takaya,<sup>b</sup> Tsuneomi Kawasaki<sup>c</sup> and Yuji Tokunaga \*<sup>a</sup>

<sup>a</sup> Department of Materials Science and Engineering, Faculty of Engineering, University of Fukui, Bunkyo, Fukui 910-8507, Japan

<sup>b</sup> International Research Center for Elements Science, Institute for Chemical Research, Kyoto University, Uji 611-0011, Japan

<sup>c</sup> Department of Applied Chemistry, Tokyo University of Science, Kagurazaka, Shinjuku-ku, Tokyo 162-8601, Japan

### TOC

1.	Experimental	2
2.	Figure S1. VT NMR spectra of the lactam 1b.	7
3.	Figure S2. VT NMR spectra of the lactam 1d.	8
4.	Figure S3. <sup>1</sup> H NMR spectra of a mixture of the lactam 1d and the bis-	
	dialkylammonium salt <b>5a</b> .	9
5.	Figure S4. <sup>1</sup> H NMR spectra of a mixture of the lactam 1d and the bis-	
	dialkylammonium salt <b>5b</b> .	10
6.	Figure S5. <sup>1</sup> H NMR spectra of a mixture of the lactam 1d and the bis-	
	dialkylammonium salt <b>5c</b> .	11
7.	Figure S6. <sup>1</sup> H NMR spectra of a mixture of the lactam <b>1a</b> and the mono-	
	dialkylammonium salt <b>5d</b> .	12
8.	Figure S7. <sup>1</sup> H NMR spectra of a mixture of the lactam 1b and the mono-	
	dialkylammonium salt <b>5d</b> .	13
9.	Figure S8. <sup>1</sup> H NMR spectra of a mixture of the lactam 1d and the mono-	
	dialkylammonium salt <b>5d</b> .	14
10.	Figure S9. 2D ROESY spectrum of a mixture of the lactam 1b and the bis-	
	dialkylammonium salt <b>5a</b> .	15
11.	Figure S10. 2D NMR spectra of the [2]rotaxane 7a.	17
12.	Figure S11. 2D NMR spectra of the [2]rotaxane 7b.	20
13.	Figure S12. 2D NMR spectra of the [2]rotaxane 7c.	23
14.	Figure S13. Mass spectrum of the [2]rotaxane 7a.	26

15. Figure S14. Mass spectrum of the [2]rotaxane 7b.	27
16. Figure S15. Mass spectrum of the [2]rotaxane 7c.	28
17. Table S1. Crystal structure data of the lactam 1b.	29
18. Figure S16 and Table S2. Crystal structure data and structure of	
the [2]rotaxane <b>7b</b> .	30
19. Figure S17. <sup>1</sup> H and <sup>13</sup> C NMR spectra of the carbamate S1.	32
20. Figure S18. <sup>1</sup> H and <sup>13</sup> C NMR spectra of the dialkylammonium salt 2	<b>2d</b> . 33
21. Figure S19. <sup>1</sup> H and <sup>13</sup> C NMR spectra of the chloride $3a$ .	34
22. Figure S20. <sup>1</sup> H and <sup>13</sup> C NMR spectra of the chloride 3b.	35
23. Figure S21. <sup>1</sup> H and <sup>13</sup> C NMR spectra of the chloride 3d.	36
24. Figure S22. <sup>1</sup> H and <sup>13</sup> C NMR spectra of the amide 4a.	37
25. Figure S23. <sup>1</sup> H and <sup>13</sup> C NMR spectra of the amide 4b.	38
26. Figure S24. <sup>1</sup> H and <sup>13</sup> C NMR spectra of the amide 4d.	39
27. Figure S25. <sup>1</sup> H and <sup>13</sup> C NMR spectra of the lactam 1a.	40
28. Figure S26. <sup>1</sup> H and <sup>13</sup> C NMR spectra of the lactam 1b.	41
29. Figure S27. <sup>1</sup> H and <sup>13</sup> C NMR spectra of the lactam 1d.	42
30. Figure S28. <sup>1</sup> H and <sup>13</sup> C NMR spectra of the dialkylammonium salt 5	<b>5b</b> . 43
31. Figure S29. <sup>1</sup> H and <sup>13</sup> C NMR spectra of the dialkylammonium salt 5	<b>5c</b> . 44
32. Figure S30. <sup>1</sup> H and <sup>13</sup> C NMR spectra of the phthalimide S2.	45
33. Figure S31. <sup>1</sup> H and <sup>13</sup> C NMR spectra of the amine 6.	46
34. Figure S32. <sup>1</sup> H and <sup>13</sup> C NMR spectra of the [2]rotaxane 7a.	47
35. Figure S33. <sup>1</sup> H and <sup>13</sup> C NMR spectra of the [2]rotaxane 7b.	48
36. Figure S34. <sup>1</sup> H and <sup>13</sup> C NMR spectra of the [2]rotaxane 7c.	49
37. Figure S35. <sup>1</sup> H and <sup>13</sup> C NMR spectra of the axle molecule 8a.	50
38. Figure S36. <sup>1</sup> H and <sup>13</sup> C NMR spectra of the axle molecule 8b.	51

## Experimental

Synthesis of the diamine 2d. Et<sup>\_N</sup>\_Boc EtN EtHN NHEt NFt Ö Boc Вос 2HCI 2d EtN NEt **Compound S1** Boc Boc **S**1

A solution of *N*-Boc-ethylamine (7.00 g, 48.3 mmol) in dry THF (60 mL) and di(ethylene glycol) ditosylate (9.10 g, 24.0 mmol) were added to a suspension of NaH (1.16 g, 48.3 mmol) in dry THF (100 mL) and then the mixture was stirred for 2 days at 40 °C. After evaporation of the solvent, the residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub>. The solution was washed with 5% NaHSO<sub>4</sub> (aq.) and sat. NaCl (aq.), dried (MgSO<sub>4</sub>), and concentrated. The residue was chromatographed (SiO<sub>2</sub>; hexane/EtOAc, 6:1) to give the carbamate **S1** (6.65 g, 77%) as a colorless oil. IR (NaCl,  $v_{max}$ , cm<sup>-1</sup>): 2974, 2933, 2874, 1685, 1412, 1364, 1284, 1165. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$ : 1.09 (br t, *J* = 6.5 Hz, 6H), 1.45 (s, 18H), 3.19–3.43 (m, 8H), 3.46–3.62 (m, 4H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>)  $\delta$ : [13.1 and 13.5 (major)], [28.2], [42.4 and 43.0 (major)], [46.4], [69.6], [78.9], [154.9 and 155.3 (major)]. HRMS (FAB) calcd for C<sub>18</sub>H<sub>37</sub>N<sub>2</sub>O<sub>5</sub><sup>+</sup> [M + H]<sup>+</sup> *m/z* 361.2702, found: 361.2696.

### **Compound 2d**

EtHN O NHEt 2d 2HCl

A solution of hydrogen chloride in 1,4-dioxane (4 M, 50 mL, 200 mmol) was added to a solution of **S1** (7.30 g, 20.3 mmol) in diethyl ether (100 mL) at room temperature. After stirring overnight, the precipitate was collected by filtration, giving **2d** (3.60 g, 76%) as a white powder. IR (KBr,  $v_{max}$ , cm<sup>-1</sup>): 3447, 2973, 2809, 1576, 1452, 1112, 801. <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ : 1.25 (t, *J* = 7.5 Hz, 6H), 2.95 (sex, *J* = 7.5 Hz, 4H), 3.04–3.12 (m, 4H), 3.69 (t, *J* = 5.3 Hz, 4H), 9.11 (br s, 4H). <sup>13</sup>C NMR (125 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ : 10.8, 41.9, 45.8, 65.3. HRMS (FAB) calcd for C<sub>8</sub>H<sub>21</sub>N<sub>2</sub>O<sup>+</sup> [M – HCl – Cl]<sup>+</sup> *m/z* 161.1654, found 161.1659.

### **Compound 3a**



A solution of chloroacetyl chloride (3.8 mL, 48 mmol) in  $CH_2Cl_2$  (100 mL) was added to a solution of N,N'-dimethylenediamine (2.4 mL, 22 mmol) in 10% NaHCO<sub>3</sub> (aq.) (120 mL, 0.11 mol) in an ice bath and then the mixture was stirred for 2 h at room temperature. The organic layer was separated, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. The residual solid was washed with hexane to afford the amide **3a** (4.50 g, 82%) as a white powder. IR (KBr,  $v_{max}$ , cm<sup>-1</sup>): 2996, 2953, 1654, 1651, 1486, 1420, 1278, 1180, 1106, 795. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$ : 3.02, 3.12 (major), and 3.15 (each s, 6H), 3.56 and 3.61 (major) (each s, 4H), 4.05 (major), 4.08, and 4.14 (each s, 4H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$ : [34.1, 35.9 (major) and 37.3], [40.6, 41.0 and 41.4 (major)], [45.1 (major), 47.1, 47.6], [166.9, 167.1 (major)].

The <sup>1</sup>H and <sup>13</sup>C NMR spectra (CDCl<sub>3</sub>) of **3a** were identical to those reported previously.<sup>S1</sup>

### **Compound 3b**



**3b** (1.83 g) was synthesized from *N*,*N*<sup>'</sup>-dimethyl-1,3-propanediamine (2.00 g, 19.6 mmol), using the procedure described above, as a white powder (93% yield). IR (KBr,  $v_{max}$ , cm<sup>-1</sup>): 2997, 2955, 2877, 1662, 1481, 1410, 1282, 1143, 1058, 790. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$ : 1.80–1.88 (major), 1.88–1.96, and 2.00–2.08 (each m, 2H), 2.96, 2.99, 3.09 (major) and 3.12 (each s, 6H), 3.34–3.49 (m, 4H), 4.08 (major) and 4.09 (each s, 4H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$ : [24.3 (major) and 26.1], [33.5, 35.6 (major), and 35.7], [40.8, 41.2, and 41.5 (major)], [45.6, 45.7 (major), and 47.9], [166.3, 166.4 (major), 166.8]. HRMS (FAB) calcd for C<sub>9</sub>H<sub>17</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> *m*/*z* 255.0662, found: 255.0666.

The <sup>13</sup>C NMR spectrum of **3b** was identical to that reported previously.<sup>S2</sup>

#### **Compound 3d**



**3d** (1.86 g) was synthesized from **2d** (1.50 g, 6.43 mmol), using the procedure described above, as a white powder (93% yield). IR (KBr,  $v_{max}$ , cm<sup>-1</sup>): 2976, 2936, 2874, 1654, 1648, 1459, 1119, 1090, 788. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$ : 1.14 (major), 1.22, and 1.23 (each t, *J* = 7.3 Hz, 6H), 3.37–3.65 (m, 12H), 4.09 (major), 4.11, and 4.18 (each s, 4H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$ : [11.0, 11.1, and 12.7 (major)], 39.8, 39.9, 40.3, 40.4, 40.6, 40.8, 42.2, 42.4, 43.8, 44.1, 46.0, [67.2, 67.3 (major), and 67.9], [164.6, 164.69 (major), 164.72, and 164.9]. HRMS (FAB) calcd for C<sub>12</sub>H<sub>23</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup> *m/z* 313.1086, found: 313.1078.

Synthesis of bis-dialkylammonium salts 5b and 5c.



A solution of trimethylenediamine (0.40 mL, 4.3 mmol) and terephthalaldehyde mono(diethylacetal) (1.9 mL, 9.6 mmol) in toluene (40 mL) was heated under reflux for 2 h using a Dean–Stark apparatus. After evaporation of the solvent, the residue was dissolved in EtOH (30 mL). NaBH<sub>4</sub> (0.33 g, 8.7 mmol) was added and then the mixture was stirred at 60 °C for 6 h. After evaporation of the solvent, the residue was treated 10%  $Na_2CO_3$  (aq.). The aqueous phase was extracted with  $CH_2Cl_2$ . The combined organic phases were washed with sat. NaCl, then dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated. The residue was dissolved in THF (20 mL) and treated with 10% HCl (aq.) (27 mL, 87 mmol) and then left at room temperature for 6 h. After evaporation of the THF, the precipitate was collected by filtration to afford the crude ammonium chloride as a solid. NH<sub>4</sub>PF<sub>6</sub> (3.6 g, 22 mmol) was added to a suspension of the crude ammonium chloride in water (30 mL) and acetone (30 mL), and then the mixture was stirred at room temperature for 2 days. After evaporation of the acetone, the precipitate was collected by filtration to afford the ammonium hexafluorophosphate **5b** (0.61 g, 24%) as a white powder. IR (KBr):  $v_{max}$ , cm<sup>-</sup> <sup>1</sup>: 2980, 2940, 2797, 1700, 830, 560. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>CN)  $\delta$ : 2.07 (quin, J = 7.9) Hz, 2H), 3.23 (t, J = 7.9 Hz, 4H), 4.28 (s, 4H), 7.08 (br s, 4H), 7.63–7.70 (m, 4H), 7.95– 8.02 (m, 4H), 10.05 (s, 2H). <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>CN) δ: 23.3, 45.9, 52.2, 131.0, 131.8, 137.2, 138.3, 193.3. HRMS (FAB) calcd for  $C_{19}H_{23}N_2O_2^+$  [M – HPF<sub>6</sub> – PF<sub>6</sub>]<sup>+</sup> m/z311.1749, found, 311.1765.

### **Compound 5c**



**5c** (6.2 g) was synthesized from 1,4-diaminobutane (1.2 g, 11 mmol) and terephthalaldehyde mono(diethylacetal) (5.0 g, 24 mmol), using the procedure described above, as a white solid (89% yield). IR (KBr,  $v_{max}$ , cm<sup>-1</sup>): 2981, 2943, 2796, 1700, 833,

560. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>CN) δ: 1.65–1.74 (m, 4H), 3.01–3.12 (m, 4H), 4.24 (s, 4H), 6.88 (br s, 4H), 7.62–7.68 (m, 4H), 7.74–8.01 (m, 4H), 10.04 (s, 2H). <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>CN) δ: 23.5, 48.3, 52.1, 130.9, 131.8, 137.4, 138.3, 193.2. HRMS (FAB) calcd for C<sub>20</sub>H<sub>25</sub>N<sub>2</sub>O<sub>2</sub><sup>+</sup> [M – HPF<sub>6</sub> – PF<sub>6</sub>]<sup>+</sup> m/z 325.1911, found: 325.1919.

Synthesis of the O-benzylhydroxylamine 6.



A solution of 3,5-di-*tert*-butyltoluene (5.00 g, 24.5 mmol), NBS (4.35 g, 24.5 mmol), and AIBN (catalytic) in benzene (80 mL) was heated under reflux overnight. After cooling, the precipitate was removed by filtration. The filtrate was washed with 10% Na<sub>2</sub>SO<sub>3</sub> (aq.) and sat NaCl (aq.) and dried (Na<sub>2</sub>SO<sub>4</sub>). Evaporation of the solvent gave the crude bromide. A solution of the crude product, *N*-hydroxyphthalimide (4.40 g, 27.0 mmol), and triethylamine (2.73 g, 27.0 mmol) in dry DMF (70 mL) was stirred at 45 °C overnight. After evaporation of the solvent, the residue was purified through column chromatography (SiO<sub>2</sub>; hexane/AcOEt, 20:1) to afford **S2** (5.20 g, 57%) as a white solid. IR (KBr,  $v_{max}$ , cm<sup>-1</sup>): 2962, 2903, 1737, 1717, 1464, 1367, 1183, 1134, 966, 879. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$ : 1.29 (s, 18H), 5.22 (s, 2H), 7.35 (d, *J* = 2.0 Hz), 7.41 (t, *J* = 2.0 Hz, 1H), 7.70–7.74 (m, 2H), 7.77–7.82 (m, 2H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$ : 31.3, 34.8, 80.5, 123.3, 124.3, 128.9, 132.6, 134.3, 151.0, 163.4. HRMS (FAB) calcd for C<sub>23</sub>H<sub>27</sub>NO<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup> *m*/z 366.2069, found, 366.2061.

### **Compound 6**



A solution of *N*-(3,5-di-*tert*-butylbenzyloxy)phthalimide (**S2**, 870 mg, 2.38 mmol) and hydrazine monohydrate (2.98 g, 59.5 mmol) in EtOH (25 mL) was stirred at 60 °C overnight. The precipitate filtered off and the filtrate concentrated. CHCl<sub>3</sub> was added to the residue and the insoluble solid was filtered off. The filtrate was washed with sat. NaCl (aq.), dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. The residue was chromatographed (SiO<sub>2</sub>;

hexane/EtOAc, 20:1) to give **6** (460 mg, 82%) as a colorless oil. IR (NaCl,  $v_{max}$ , cm<sup>-1</sup>): 3315, 3242, 3154, 2963, 2905, 2867, 1600, 1478, 1363, 1249, 998, 895, 865, 714. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$ : 1.33 (s, 18H), 4.69 (s, 2H), 5.38 (br s, 2H), 7.29 (d, J = 2.0 Hz, 2H), 7.39 (t, J = 2.0 Hz, 1H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>)  $\delta$ : 31.4, 34.7, 78.8, 122.1, 122.5, 136.2, 150.8. HRMS (FAB) calcd for C<sub>15</sub>H<sub>26</sub>NO<sup>+</sup> [M + H]<sup>+</sup> *m*/*z* 236.2014, found, 236.2021.

### Axle molecule 8a

A solution of mono-ammonium salt **5a** (126 mg, 210 µmol) and **6** (122 mg, 518 µmol) in acetonitrile (2 mL) was stirred at room temperature overnight. After evaporation of the solvent, the residue was washed with hexane to give **8a** as a white powder (150 mg, 70%). IR (KBr,  $v_{max}$ , cm<sup>-1</sup>): 3644, 3579, 3233, 2964, 1601, 1464, 1423, 1363, 1249, 1203, 1015, 996, 841, 558. <sup>1</sup>H NMR (600 MHz, DMSO-*d*<sub>6</sub>) for major isomer  $\delta$ : 1.28 (s, 36H), 3.24 (br s, 4H), 4.24 (br s, 4H), 5.16 (s, 4H), 7.24 (br s, 4H), 7.35 (br s, 2H), 7.49–7.55 (m, 4H), 7.69–7.75 (m, 4H), 8.35 (s, 2H), 8.86 (br s, 4H). <sup>13</sup>C NMR (150 MHz, DMSO-*d*<sub>6</sub>) for major isomer  $\delta$ : 31.3, 34.5, 42.5, 50.1, 76.4, 121.5, 122.6, 127.2, 130.3, 132.9, 133.2, 136.4, 148.5, 150.3. HRMS (FAB) calcd for C<sub>48</sub>H<sub>67</sub>N<sub>4</sub>O<sub>2</sub><sup>+</sup> [M – HPF<sub>6</sub> – PF<sub>6</sub>]<sup>+</sup> *m/z* 731.5259, found: 731.5255.

#### Axle molecule 8b

**8b** (80.0 mg, 70%) was synthesized from mono-ammonium salt **5d** (50.5 mg, 126  $\mu$ mol) and **6** (113 mg, 480  $\mu$ mol), using the procedure described above, as a white powder. IR (KBr,  $\nu_{max}$ , cm<sup>-1</sup>): 3649, 3257, 3229, 2964, 1601, 1476, 1465, 1419, 1411, 1363, 1249, 1203, 1016, 997, 847, 558. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) for major isomer  $\delta$ : 1.32 (s, 36H), 4.13–4.19 (m, 4H), 5.18 (s, 4H), 6.75 (br s, 2H), 7.26 (br s, 4H), 7.34–7.42 (m, 6H), 7.61–7.65 (m, 4H), 8.07 (s, 2H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) for major isomer  $\delta$ : 31.4, 34.8, 51.1, 77.6, 122.3, 123.0, 128.0, 129.8, 130.2, 134.4, 135.8, 147.5, 150.9. HRMS (FAB) calcd for C<sub>46</sub>H<sub>62</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M – PF<sub>6</sub>]<sup>+</sup> *m/z* 688.4837, found: 688.4841.

#### References

- S1. T. C. Pickel, G. J. Karahalis, C. T. Buru, J. Bacsa and C. C. Scarborough, *Eur. J. Org. Chem.*, 2018, 6876–6889.
- S2. T. Rodopoulos, K. Ishihara, M. Rodopoulos, M. J. Zaworotko, M. Maeder and A. McAuley, *Can. J. Chem.*, 2005, 83, 894–902.



**Figure S1.** <sup>1</sup>H NMR spectra (600 MHz, DMSO- $d_6$ ) of the lactam **1b**, recorded at 25–125 °C.



**Figure S2.** <sup>1</sup>H NMR spectra (600 MHz, DMSO- $d_6$ ) of the lactam **1d**, recorded at 25–125 °C.



**Figure S3.** <sup>1</sup>H NMR spectra [600 MHz, CDCl<sub>3</sub>/CD<sub>3</sub>CN (1:1), 25 °C] of (a) the lactam **1d**, (b) a mixture of **1d** (3 mM) and **5a** (3 mM), and (c) **5a**.



**Figure S4.** <sup>1</sup>H NMR spectra [600 MHz, CDCl<sub>3</sub>/CD<sub>3</sub>CN (1:1), 25 °C] of (a) the lactam **1d**, (b) a mixture of **1d** (3 mM) and **5b** (3 mM), and (c) **5b**.



**Figure S5.** <sup>1</sup>H NMR spectra [600 MHz, CDCl<sub>3</sub>/CD<sub>3</sub>CN (1:1), 25 °C] of (a) the lactam **1d**, (b) a mixture of **1d** (3 mM) and **5c** (3 mM), and (c) **5c**.



**Figure S6.** (a–d) <sup>1</sup>H NMR spectra [600 MHz, CDCl<sub>3</sub>/CD<sub>3</sub>CN (1:1), 25 °C] of (a) **1a**, (b) a mixture of **1a** (3 mM) and **5d** (3 mM), (c) **5d**, and (d) the sample in (b) plus **6** (4 eq). (e–g) <sup>1</sup>H NMR spectra (600 MHz, DMSO- $d_6$ , 25 °C) of (e) the sample in (d) after exchange of the mixed solvent for DMSO- $d_6$ , (f) **1a**, and (g) the axle molecule **8b**.  $\blacktriangle$ : **8b**;  $\blacksquare$ : **1a**.



**Figure S7.** <sup>1</sup>H NMR spectra [500 MHz, CDCl<sub>3</sub>/CD<sub>3</sub>CN (1:1), 25 °C] of (a) **1b**, (b) a mixture of **1b** (3 mM), **5d** (3 mM), and (c) **5d**.



**Figure S8.** (a–d) <sup>1</sup>H NMR spectra [600 MHz, CDCl<sub>3</sub>/CD<sub>3</sub>CN (1:1), 25 °C] of (a) **1d**, (b) a mixture of **1d** (3 mM) and **5d** (9 mM), (c) **5d**, and (d) the sample in (b) plus **6** (3 eq for **5d**). (e–g) <sup>1</sup>H NMR spectra (600 MHz, DMSO- $d_6$ , 25 °C) of (e) the sample in (d) after exchange of the mixed solvent for DMSO- $d_6$ , (f) **1d**, and (g) the axle molecule **8b**.  $\blacktriangle$  : **8b**; d.







**Figure S9.** ROESY [600 MHz, CDCl<sub>3</sub>/CD<sub>3</sub>CN (1:1)] spectrum of a mixture of the lactam **1b** (5 mM) and the bis-dialkylammonium salt **5a** (5 mM).



Figure S10a. COSY (600 MHz, CD<sub>3</sub>CN) spectrum of the [2]rotaxane 7a.







Figure S10b. ROESY (600 MHz,  $CD_3CN$ ) spectrum of the [2]rotaxane 7a.





Figure S11a. COSY (600 MHz, CDCl<sub>3</sub>) spectrum of the [2]rotaxane 7b.





Figure S11b. ROESY (600 MHz, CDCl<sub>3</sub>) spectrum of the [2]rotaxane 7b.





Figure S12a. COSY (600 MHz, CDCl<sub>3</sub>) spectrum of the [2]rotaxane 7c.







Figure S12b. ROESY (600 MHz, CDCl<sub>3</sub>) spectrum of the [2]rotaxane 7c.



**Figure S13.** MALDI-TOF mass spectrum of the [2]rotaxane **7a**. Upper: experimental isotopic pattern; lower: calculated isotopic pattern.



**Figure S14.** MALDI-TOF mass spectrum of the [2]rotaxane **7b**. Upper: experimental isotopic pattern; lower: calculated isotopic pattern.



**Figure S15.** MALDI-TOF spectrum of the [2]rotaxane **7c**. Upper: experimental isotopic pattern; lower: calculated isotopic pattern.

 Table S1. Crystal data and structure refinement parameters for the lactam 1b.

Empirical Formula	$C_{34}H_{44}Cl_{12}N_4O_8\\$
Formula Weight	1062.18
Temperature	–100.0 °C
Crystal System	triclinic
Space Group	P-1 (#2)
Lattice Parameters	a = 10.0502(3) Å
	b = 10.8877(4) Å
	c = 11.4091(4) Å
	$\alpha = 84.205(6)^{\circ}$
	$\beta = 74.087(5)^{\circ}$
	$\gamma = 78.083(6)^{\circ}$
Volume	1173.39(8) Å <sup>3</sup>
Z value	1
$ ho_{ m calc}$	$1.503 \text{ g/cm}^3$
F (000)	544.00
Crystal Color	colorless
Crystal Size	$0.540 \times 0.300 \times 0.120 \text{ mm}$
Radiation	Mo K $\alpha$ ( $\lambda = 0.71075$ Å)
$2\theta_{\rm max}$	54.9°
Number of Reflections Measured	Total: 23419
	Unique: 5354 ( $R_{int} = 0.0244$ )
Goodness-of-Fit on $F^2$	1.047
Residuals: $R_1 [I > 2.00\sigma (I)]$	0.0836
Residuals: $wR_2$ (All reflections)	0.2322



**Figure S16.** Crystal structure of the [2]rotaxane **7b**. The major (a, b) NH···O and (c, d) CH···O interactions are highlighted with dotted lines. Hydrogen bond distances (Å): (a, b) 2.73 [N(1)<sup>+</sup>···O(1)], 2.65 [N(1)<sup>+</sup>···O(2)], 1.96 [H(1)···O(1)], 1.89 [H(2)···O(2)], 2.54 [H(1)···O(3)], 2.51 [H(2)···O(4)]; (c, d) 2.53 [H(3)<sup>-</sup>···O(1)], 2.72 [H(4)<sup>-</sup>···O(2)], 2.70 [H(3)<sup>-</sup>···O(3)], 2.50 [H(4)<sup>-</sup>···O(4)]. Hydrogen bond angles (deg): N(1)<sup>+</sup>–H(1)···O(1) and N(1)<sup>+</sup>–H(2)···O(2), 141 and 140, respectively. Hydrogen atoms, PF<sub>6</sub><sup>-</sup> ions, and <sup>*t*</sup>Bu disorder have been omitted for clarity.

 Table S2. Crystal data and structure refinement parameters for the [2]rotaxane 7b.

Empirical Formula	$C_{78}H_{108}F_{12}N_8O_{10}P_2$
Formula Weight	1607.69
Temperature	−100.0 °C
Crystal System	triclinic
Space Group	P-1 (#2)
Lattice Parameters	a = 8.69360  Å
	<i>b</i> = 11.55039 Å
	<i>c</i> = 22.97133 Å
	$\alpha = 79.01400^{\circ}$
	$\beta = 79.44700^{\circ}$
	$\gamma = 65.70200^{\circ}$
Volume	2049.61022 Å <sup>3</sup>
Z value	1
$ ho_{ m calc}$	1.302 g/cm <sup>3</sup>
F (000)	850.00
Crystal Color	colorless
Crystal Size	$0.010 \times 0.010 \times 0.010 \text{ mm}$
Radiation	Synchrotron ( $\lambda = 0.81078$ Å)
$2\theta_{\rm max}$	58.5°
Number of Reflections Measured	Total: 21074
	Unique: 7442 ( <i>R</i> <sub>int</sub> = 0.1011)
Goodness-of-Fit on $F^2$	1.131
Residuals: $R_1 [I > 2.00\sigma(I)]$	0.1434
Residuals: $wR_2$ (All reflections)	0.4088



Figure S17a. <sup>1</sup>H NMR spectrum (500 MHz, CDCl<sub>3</sub>) of the carbamate S1.



Figure S17b. <sup>13</sup>C NMR spectrum (150 MHz, CDCl<sub>3</sub>) of the carbamate S1.



**Figure S18a.** <sup>1</sup>H NMR spectrum (500 MHz, DMSO-*d*<sub>6</sub>) of the dialkylammonium salt **2d**.



**Figure S18b.** <sup>13</sup>C NMR spectrum (125 MHz, DMSO-*d*<sub>6</sub>) of the dialkylammonium salt **2d**.



Figure S19a. <sup>1</sup>H NMR spectrum (500 MHz, CDCl<sub>3</sub>) of the chloride 3a.



Figure S19b. <sup>13</sup>C NMR spectrum (125 MHz, CDCl<sub>3</sub>) of the chloride 3a.



Figure S20a. <sup>1</sup>H NMR spectrum (500 MHz, CDCl<sub>3</sub>) of the chloride 3b.



Figure S20b. <sup>13</sup>C NMR spectrum (125 MHz, CDCl<sub>3</sub>) of the chloride 3b.



Figure S21a. <sup>1</sup>H NMR spectrum (500 MHz, CDCl<sub>3</sub>) of the chloride 3d.



Figure S21b. <sup>13</sup>C NMR spectrum (125 MHz, CDCl<sub>3</sub>) of the chloride 3d.



Figure S22a. <sup>1</sup>H NMR spectrum (500 MHz, CDCl<sub>3</sub>) of the amide 4a.



Figure S22b. <sup>13</sup>C NMR spectrum (125 MHz, CDCl<sub>3</sub>) of the amide 4a.



Figure S23a. <sup>1</sup>H NMR spectrum (500 MHz, CDCl<sub>3</sub>) of the amide 4b.



Figure S23b. <sup>13</sup>C NMR spectrum (125 MHz, CDCl<sub>3</sub>) of the amide 4b.



Figure S24a. <sup>1</sup>H NMR spectrum (600 MHz, CDCl<sub>3</sub>) of the amide 4d.



Figure S24b. <sup>13</sup>C NMR spectrum (125 MHz, CDCl<sub>3</sub>) of the amide 4d.



Figure S25a. <sup>1</sup>H NMR spectrum (500 MHz, CDCl<sub>3</sub>) of the cyclic tetraamide 1a.



Figure S25b. <sup>13</sup>C NMR spectrum (125 MHz, CDCl<sub>3</sub>) of the cyclic tetraamide 1a.



Figure S26a. <sup>1</sup>H NMR spectrum (500 MHz, CDCl<sub>3</sub>) of the cyclic tetraamide 1b.



Figure S26b. <sup>13</sup>C NMR spectrum (125 MHz, CDCl<sub>3</sub>) of the cyclic tetraamide 1b.



Figure S27a. <sup>1</sup>H NMR spectrum (500 MHz, CDCl<sub>3</sub>) of the cyclic tetraamide 1d.



Figure S27b. <sup>13</sup>C NMR spectrum (125 MHz, CDCl<sub>3</sub>) of the cyclic tetraamide 1d.



Figure S28a. <sup>1</sup>H NMR spectrum (500 MHz, CD<sub>3</sub>CN) of the ammonium salt 5b.



Figure S28b. <sup>13</sup>C NMR spectrum (125 MHz, CD<sub>3</sub>CN) of the ammonium salt 5b.



Figure S29a. <sup>1</sup>H NMR spectrum (500 MHz, CD<sub>3</sub>CN) of the dialkylammonium salt 5c.



Figure S29b. <sup>13</sup>C NMR spectrum (125 MHz, CD<sub>3</sub>CN) of the dialkylammonium salt 5c.



Figure S30a. <sup>1</sup>H NMR spectrum (500 MHz, CDCl<sub>3</sub>) of the phthalimide S2.



Figure S30b. <sup>13</sup>C NMR spectrum (125 MHz, CDCl<sub>3</sub>) of the phthalimide S2.



Figure S31a. <sup>1</sup>H NMR spectrum (500 MHz, CDCl<sub>3</sub>) of the *O*-benzylhydroxylamine 6.



Figure S31b. <sup>13</sup>C NMR spectrum (125 MHz, CDCl<sub>3</sub>) of the *O*-benzylhydroxylamine 6.



Figure S32a. <sup>1</sup>H NMR spectrum (600 MHz, CD<sub>3</sub>CN) of the [2]rotaxane 7a.



Figure S32b. <sup>13</sup>C NMR spectrum (150 MHz, CD<sub>3</sub>CN) of the [2]rotaxane 7a.



Figure S33a. <sup>1</sup>H NMR spectrum (600 MHz, CDCl<sub>3</sub>) of the [2]rotaxane 7b.



Figure S33b. <sup>13</sup>C NMR spectrum (150 MHz, CDCl<sub>3</sub>) of the [2]rotaxane 7b.



**Figure S34a.** <sup>1</sup>H NMR spectrum (600 MHz, CDCl<sub>3</sub>) of the [2]rotaxane **7c**.



Figure S34b. <sup>13</sup>C NMR spectrum (150 MHz, CDCl<sub>3</sub>) of the [2]rotaxane 7c.



**Figure S35a.** <sup>1</sup>H NMR spectrum (600 MHz, DMSO-*d*<sub>6</sub>) of the axle molecule **8a**.



Figure S35b. <sup>13</sup>C NMR spectrum (150 MHz, DMSO- $d_6$ ) of the axle molecule 8a.



Figure S36a. <sup>1</sup>H NMR spectrum (600 MHz, CDCl<sub>3</sub>) of the axle molecule 8b.



Figure S36b. <sup>13</sup>C NMR spectrum (150 MHz, CDCl<sub>3</sub>) of the axle molecule 8b.